BioSpace News Archive

Aquestive Therapeutics, Inc. announced the publication of a crossover food effect pharmacokinetic study of diazepam nasal spray in the peer-reviewed scientific journal Epilepsia.

Applied Genetic Technologies Corporation, announced that a portfolio company of Syncona Limited has extended the expiration of its previously announced tender offer to purchase all of the issued and outstanding shares of AGTC common stock for $0.34 per share in cash at closing, plus up to an additional $0.73 per share payable pursuant to contingent value rights upon the achievement of specified milestones.

BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that more than 316 patients have enrolled in its Phase 3 trial, thereby achieving its trial enrollment target.

Capstone Development Services Company LLC (“Capstone”) announced today that a biosimilar version of human insulin received authorization from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) and a Notice of Compliance from Health Canada.

RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today reported its third quarter 2022 financial results and operational highlights.

SOFIE Biosciences (SOFIE), an established US manufacturer and developer of radiopharmaceuticals, has received Investigational New Drug (IND) clearance to proceed with clinical study of [18F]FAPI-74, its lead fluorine-18 labelled Fibroblast Activation Protein Inhibitor (FAPI) product.

AIVITA Biomedical, Inc. announced that chief medical officer Robert O. Dillman, M.D., will chair and deliver the opening remarks for the Cancer Immunotherapy track at World Vaccine and Immunotherapy Congress West Coast, taking place Nov 28 – Dec 1 in San Diego, California.

IceCure Medical Ltd., developer of minimally-invasive cryoablation technology, the ProSense® System that destroys tumors by freezing as an alternative to surgical tumor removal, announced it will report its business and financial results as of and for the nine months ended September 30, 2022 on Monday, December 5, 2022 with a press release issued at 7:00 a.m. EST.

Thryv Therapeutics Inc. is pleased to announce the appointment of Melissa Koomey to its Board of Directors.

Viatris Inc. announced that it has closed its transaction with Biocon Biologics Limited, creating what Viatris expects to be a unique fully vertically integrated global biosimilars leader.